Friederike Herbst

7PUBLICATIONS
86CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.

Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall

|Nov 13, 2024
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function.

Alexander J Dimitri, Amy E Baxter, Gregory M Chen

|Aug 31, 2023
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.

Nils Wellhausen, Ryan P O'Connell, Stefanie Lesch

|Apr 03, 2023
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.

In-Young Jung, Robert L Bartoszek, Andrew J Rech

|May 22, 2021
The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision.

Friederike Herbst, Tonio J L Lang, Elias S P Eckert

|Apr 03, 2021
Functional States in Tumor-Initiating Cell Differentiation in Human Colorectal Cancer.

Martina K Zowada, Stephan M Tirier, Sebastian M Dieter

Pageof 2